In recent years, glucagon-like peptide-1 (GLP-1) receptor agonists have gained widespread popularity for the treatment of obesity and type 2 diabetes due to their potent effects on weight loss, glycemic control, and cardiovascular risk reduction [1]. This evidence concerns the gene GCG and obesity due to melanocortin 4 receptor deficiency.